{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "DJ-1",
        "Protein_Change": {
          "ref": "L",
          "alt": "P",
          "position": "166"
        },
        "variant_string_id": "DJ-1 L166P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in DJ-1 are associated with recessive, early onset Parkinson's disease (PD).  Mutations identified so far are recessive and thus likely to represent loss of function variants.",
          "judgment": "Yes",
          "reasoning": "The paper indicates that DJ-1 mutations are associated with early-onset Parkinson's disease and are likely loss-of-function variants.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper assesses protein stability and subcellular localization. 'We reported previously that one of the point mutations, L166P, destabilizes the protein and thus produces an effective knockout of the gene.'",
          "judgment": "Yes",
          "reasoning": "Protein stability and localization assays are relevant for assessing loss-of-function mechanisms in DJ-1, which is implicated in Parkinson's disease pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Western blotting was performed exactly as described [4]. The antibodies used were monoclonal anti-DJ1 (1:2500; Stressgen, Victoria, BC, Canada), monoclonal anti-V5 (1:2000; Invitrogen), and anti-ẞ actin (1:2000; Sigma).",
          "judgment": "Yes",
          "reasoning": "The paper describes using wild-type DJ-1 and beta-actin as controls. The paper mentions performing triplicate transfections.  This suggests replicates are used.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The paper used the R98Q variant and wild-type as controls.",
          "judgment": "No",
          "reasoning": "The paper doesn't mention using known pathogenic or known benign variants, or variants classified without PS3/BS3 evidence, as controls in their assays.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": null,
          "judgment": "N/A",
          "reasoning": "The step was skipped as the previous step provided a strength.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper uses R98Q and wild-type as controls.",
          "judgment": "No",
          "reasoning": "There are fewer than 11 total benign/pathogenic control variants used across the entire study.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The L166P variant is shown to have reduced protein stability, indicating a loss-of-function. Basic controls are present, but the variant controls are not pathogenic or benign, which makes the final strength PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "DJ-1",
        "Protein_Change": {
          "ref": "M",
          "alt": "I",
          "position": "26"
        },
        "variant_string_id": "DJ-1 M26I"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in DJ-1 are associated with recessive, early onset Parkinson's disease (PD).  Mutations identified so far are recessive and thus likely to represent loss of function variants.",
          "judgment": "Yes",
          "reasoning": "The paper indicates that DJ-1 mutations are associated with early-onset Parkinson's disease and are likely loss-of-function variants.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper assesses protein stability and subcellular localization. 'The M26I point mutation was also unstable, although the effect was not as dramatic as with L166P. Protein levels were rescued in part, but not completely, by proteasome inhibition.'",
          "judgment": "Yes",
          "reasoning": "Protein stability and localization assays are relevant for assessing loss-of-function mechanisms in DJ-1, which is implicated in Parkinson's disease pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Western blotting was performed exactly as described [4]. The antibodies used were monoclonal anti-DJ1 (1:2500; Stressgen, Victoria, BC, Canada), monoclonal anti-V5 (1:2000; Invitrogen), and anti-ẞ actin (1:2000; Sigma).",
          "judgment": "Yes",
          "reasoning": "The paper describes using wild-type DJ-1 and beta-actin as controls. The paper mentions performing triplicate transfections.  This suggests replicates are used.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The paper used the R98Q variant and wild-type as controls.",
          "judgment": "No",
          "reasoning": "The paper doesn't mention using known pathogenic or known benign variants, or variants classified without PS3/BS3 evidence, as controls in their assays.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": null,
          "judgment": "N/A",
          "reasoning": "The step was skipped as the previous step provided a strength.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper uses R98Q and wild-type as controls.",
          "judgment": "No",
          "reasoning": "There are fewer than 11 total benign/pathogenic control variants used across the entire study.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The M26I variant shows decreased protein stability, which is suggestive of loss-of-function. Because there aren't characterized variant controls, the strength is only PS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "DJ-1",
        "Protein_Change": {
          "ref": "R",
          "alt": "Q",
          "position": "98"
        },
        "variant_string_id": "DJ-1 R98Q"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in DJ-1 are associated with recessive, early onset Parkinson's disease (PD).  Mutations identified so far are recessive and thus likely to represent loss of function variants.",
          "judgment": "Yes",
          "reasoning": "The paper indicates that DJ-1 mutations are associated with early-onset Parkinson's disease and are likely loss-of-function variants.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper assesses protein stability and subcellular localization. 'Other variants, such as R98Q, were generally stable.'",
          "judgment": "Yes",
          "reasoning": "Protein stability and localization assays are relevant for assessing loss-of-function mechanisms in DJ-1, which is implicated in Parkinson's disease pathogenesis. Showing that it is stable is suggestive of a benign/normal function.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Western blotting was performed exactly as described [4]. The antibodies used were monoclonal anti-DJ1 (1:2500; Stressgen, Victoria, BC, Canada), monoclonal anti-V5 (1:2000; Invitrogen), and anti-ẞ actin (1:2000; Sigma).",
          "judgment": "Yes",
          "reasoning": "The paper describes using wild-type DJ-1 and beta-actin as controls. The paper mentions performing triplicate transfections. This suggests replicates are used.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The paper used wild-type protein as a control.",
          "judgment": "No",
          "reasoning": "The paper doesn't mention using known pathogenic or known benign variants, or variants classified without PS3/BS3 evidence, as controls in their assays, besides the wild-type protein.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": null,
          "judgment": "N/A",
          "reasoning": "The step was skipped as the previous step provided a strength.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper uses wild-type as controls.",
          "judgment": "No",
          "reasoning": "There are fewer than 11 total benign/pathogenic control variants used across the entire study.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_supporting"
      },
      "overall_conclusion": "The R98Q variant shows similar stability to wild-type DJ-1, suggesting a benign effect. However, without using characterized benign variant controls, the strength is only BS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "DJ-1",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "104"
        },
        "variant_string_id": "DJ-1 A104T"
      },
      "functional_evidence_aim": "Unknown",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in DJ-1 are associated with recessive, early onset Parkinson's disease (PD).  Mutations identified so far are recessive and thus likely to represent loss of function variants.",
          "judgment": "Yes",
          "reasoning": "The paper indicates that DJ-1 mutations are associated with early-onset Parkinson's disease and are likely loss-of-function variants.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper assesses protein stability and subcellular localization. 'Other variants, such as A104T, were generally stable.'",
          "judgment": "Yes",
          "reasoning": "Protein stability and localization assays are relevant for assessing loss-of-function mechanisms in DJ-1, which is implicated in Parkinson's disease pathogenesis. Showing that it is stable is suggestive of a normal function.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Western blotting was performed exactly as described [4]. The antibodies used were monoclonal anti-DJ1 (1:2500; Stressgen, Victoria, BC, Canada), monoclonal anti-V5 (1:2000; Invitrogen), and anti-ẞ actin (1:2000; Sigma).",
          "judgment": "Yes",
          "reasoning": "The paper describes using wild-type DJ-1 and beta-actin as controls. The paper mentions performing triplicate transfections. This suggests replicates are used.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The paper used wild-type protein as a control.",
          "judgment": "No",
          "reasoning": "The paper doesn't mention using known pathogenic or known benign variants, or variants classified without PS3/BS3 evidence, as controls in their assays, besides the wild-type protein.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": null,
          "judgment": "N/A",
          "reasoning": "The step was skipped as the previous step provided a strength.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper uses wild-type as controls.",
          "judgment": "No",
          "reasoning": "There are fewer than 11 total benign/pathogenic control variants used across the entire study.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_supporting"
      },
      "overall_conclusion": "The A104T variant shows similar stability to wild-type DJ-1, suggesting a normal function. However, without using characterized benign variant controls, the strength is only BS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "DJ-1",
        "Protein_Change": {
          "ref": "D",
          "alt": "A",
          "position": "149"
        },
        "variant_string_id": "DJ-1 D149A"
      },
      "functional_evidence_aim": "Unknown",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in DJ-1 are associated with recessive, early onset Parkinson's disease (PD).  Mutations identified so far are recessive and thus likely to represent loss of function variants.",
          "judgment": "Yes",
          "reasoning": "The paper indicates that DJ-1 mutations are associated with early-onset Parkinson's disease and are likely loss-of-function variants.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper assesses protein stability and subcellular localization. 'Other variants, such as D149A, were generally stable.'",
          "judgment": "Yes",
          "reasoning": "Protein stability and localization assays are relevant for assessing loss-of-function mechanisms in DJ-1, which is implicated in Parkinson's disease pathogenesis. Showing that it is stable is suggestive of a normal function.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Western blotting was performed exactly as described [4]. The antibodies used were monoclonal anti-DJ1 (1:2500; Stressgen, Victoria, BC, Canada), monoclonal anti-V5 (1:2000; Invitrogen), and anti-ẞ actin (1:2000; Sigma).",
          "judgment": "Yes",
          "reasoning": "The paper describes using wild-type DJ-1 and beta-actin as controls. The paper mentions performing triplicate transfections. This suggests replicates are used.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The paper used wild-type protein as a control.",
          "judgment": "No",
          "reasoning": "The paper doesn't mention using known pathogenic or known benign variants, or variants classified without PS3/BS3 evidence, as controls in their assays, besides the wild-type protein.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": null,
          "judgment": "N/A",
          "reasoning": "The step was skipped as the previous step provided a strength.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper uses wild-type as controls.",
          "judgment": "No",
          "reasoning": "There are fewer than 11 total benign/pathogenic control variants used across the entire study.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_supporting"
      },
      "overall_conclusion": "The D149A variant shows similar stability to wild-type DJ-1, suggesting a normal function. However, without using characterized benign variant controls, the strength is only BS3_supporting."
    }
  ]
}
